I’ve worked on both the sponsor and vendor sides. And over time, I’ve noticed a consistent pattern.

Sponsors can be cagey. CROs become defensive. And performance suffers.

This isn’t about bad intent. It’s about how transparency breaks down — often early — and the system reacts exactly as you would expect.

The RFP Stage

Not everything is finalized internally. Clinical science is debating details. Budget pressure exists but isn’t explicitly stated. Enrollment assumptions are still evolving. So information gets softened or held back.

The reasoning sounds reasonable:

  • “It’s not finalized internally.”

  • “Let’s not create confusion.”

  • “We’ll sort it out after award.”

But when vendors don’t see the full operating environment, they compensate. They price defensively. They insert protective assumptions. They leave flexibility where clarity should have existed. Later, those gaps show up as scope debates and change orders.

In many cases, the issue wasn’t CRO or vendor behavior.

It was incomplete visibility at the start.

During Execution: The Amendment Example

The same dynamic appears during study conduct. A common situation:

  • Clinical science is working on a potential protocol amendment.

  • It’s not finalized internally.

  • So the CRO isn’t informed

I understand the caution. But CROs are already under strict confidentiality. And they are the ones executing the study.

If an amendment is likely — even if not confirmed — early awareness allows the CRO to:

  • Plan resource scenarios

  • Anticipate timeline shifts

  • Prepare regulatory adjustments

  • Manage site expectations

When the amendment suddenly becomes “final” and the CRO hears about it for the first time, execution compresses.

Timelines move. Budgets adjust. Tension rises.

That tension often gets labeled as defensiveness. But defensiveness is usually a response to uncertainty.

Article content

The System Reaction

In my observation, when sponsors withhold information, CROs adapt.

  • They protect margin.

  • They document assumptions more aggressively.

  • They escalate faster.

  • They rely more heavily on contractual language.

  • From the sponsor side, this looks rigid. From the CRO side, it looks prudent.

  • The system behaves exactly as designed. Limited transparency produces protective behavior.

Confidential Doesn’t Mean Silent

There is a difference between public disclosure and operational transparency.

Saying:

“This isn’t finalized internally, but there is a strong likelihood this will move forward.”

is not reckless.

It is responsible partnership. It allows preparation without committing to a final position. In my experience, early visibility reduces volatility more effectively than tighter governance ever will.

Final Observation

Transparency operates at a higher leverage point.

When sponsors are clear — even about uncertainty — CROs respond with alignment instead of defense.

Cagey sponsors create defensive CROs. Transparent sponsors create stable partnerships.

And the difference shows up in budgets, timelines, and trust.

This pattern is why we built Clin.AI the way we did.

At the RFP stage, we help sponsors structure requirements so vendors respond to clear, documented assumptions — not partial inputs. When expectations are visible, proposals are more meaningful and comparable.

During study execution, we embed visibility into the process. Assumptions are tracked. Changes are documented. Transparency becomes part of the operating model.

Vendor management shifts from reactive to proactive.

What We Do at Clin.AI

At Clin.AI, we help sponsors select and manage their vendors more effectively — making it easier to keep studies on track, within budget, and delivered on time. If you’d like to strengthen your vendor oversight and gain real-time visibility into the progress of your trials, give us a call. We’d be happy to walk you through how we can support your goals.

If that resonates with you, let's talk.

👉 Schedule a Demo

About the Author

Kalyan Obalampalli (KO) is the Founder and President of Clin.AI, a disruptive start-up transforming how biotech and pharma sponsors select and manage vendors. With more than 20 years of leadership experience in clinical operations and outsourcing at major pharma and biotech companies, KO brings a unique perspective on how technology can close long-standing gaps in clinical development.

#clinicaltrials #vendorManagement #clinicaloperations #qualitytracking

#budgetoversight #scalingbiotech #startuplife #buildingsystems #KOscorner